- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01320488
Breast Cancer in Young Women: Is it Different? (YoungWomen)
May 12, 2016 updated by: National Guard Health Affairs
Breast cancer is the leading cancer among women in Saudi Arabia representing almost the third of cancer diagnosed in Saudi women.
Breast cancer in Saudi women is more frequently observed at young age.
The data on this observation is either lacking or scares.
Furthermore, the pathological and molecular features of breast cancer in young women are not clear.
The study will provide important information to the national health care planner about this disease in young women including shedding light on possible genetic risk factors
Study Overview
Status
Suspended
Conditions
Detailed Description
The study is a prospective longitudinal cohort study of young women with breast cancer.
Over a 3-year period, we aim to identify a total of 600 women with newly diagnosed breast cancer, of those 300 women age 40 and younger and 300 older women from academic and community health care institutions across the Riyadh area.
It is anticipated at least 400 of these women will agree to participate in the study.
The comparable control group of older patients with breast cancer will be used for study comparison.
Patient surveys, medical record review, and blood and tissue collection will be utilized.
Women will be surveyed every 6 months after diagnosis.
The study will investigate short and long-term disease and treatment issues, and psychosocial concerns.
We will also collect tumor and blood samples to characterize the pathological and molecular aspects of tumors, and establish tumor bank for future studies.
Study Type
Observational
Enrollment (Anticipated)
600
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Riyadh, Saudi Arabia, 11426
- King Abdul Aziz Medical City for National Guard Health Affairs
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
The proposed project is a prospective longitudinal cohort study of young women with breast cancer.
Over a 3-year period, we aim to identify a total of 600 women with newly diagnosed breast cancer, of those 300 women age 40 and younger and 300 older women from academic and community health care institutions across the Riyadh area.
It is anticipated that at least 400 of these women (from study and control group) will agree to participate in the study.
Description
Inclusion Criteria:
- Female
- Diagnosis of breast cancer
- Age 40 or younger at diagnosis for study group and older women for control group
- Informed consent obtained from patient
Exclusion Criteria:
- Absence of informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
experience of breast cancer in young women
Time Frame: 10 years
|
To identify a cohort of young women (age 40 or younger) newly diagnosed with breast cancer in King Abdulaziz Medical City and other collaborating hospitals to assess a broad range of variables at baseline and over the course.
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Omalkahir Abulkhair, MD, King Abdul Aziz Medical City for National Guard
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Anticipated)
August 1, 2016
Study Completion (Anticipated)
August 1, 2016
Study Registration Dates
First Submitted
March 19, 2011
First Submitted That Met QC Criteria
March 19, 2011
First Posted (Estimate)
March 22, 2011
Study Record Updates
Last Update Posted (Estimate)
May 13, 2016
Last Update Submitted That Met QC Criteria
May 12, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC08/117
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female Breast Cancer
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Eli Lilly and CompanyActive, not recruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Endometrial CancerUnited States, Spain, France, Belgium, Taiwan, Australia, Korea, Republic of, Japan
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); University of Pittsburgh; Case Western Reserve...RecruitingBreast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Stage III Breast CancerUnited States
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia